# Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease

> **NCT04656704** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Brigham and Women's Hospital**

## Conditions studied

- Microstomia
- Scleroderma
- CREST Syndrome
- Scleromyxedema
- Morphea

## Interventions

- **DRUG:** hyaluronidase injected intradermally

## Key facts

- **NCT ID:** NCT04656704
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI no longer pursuing clinical trial
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656704, "Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04656704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*